Warning: The NCBI web site requires JavaScript to function. more...
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M.
Retrovirology. 2008 Oct 16;5:93.
Related citations
The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent.
Yu H, Alfsen A, Tudor D, Bomsel M.
Cell Calcium. 2008 Jan;43(1):73-82. Epub 2007 Jun 5.
Peptide and non-peptide HIV fusion inhibitors.
Jiang S, Zhao Q, Debnath AK.
Curr Pharm Des. 2002;8(8):563-80. Review.
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q.
J Virol. 2008 Jul;82(13):6349-58. Epub 2008 Apr 16.
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
Naito T, Izumi K, Kodama E, Sakagami Y, Kajiwara K, Nishikawa H, Watanabe K, Sarafianos SG, Oishi S, Fujii N, Matsuoka M.
Antimicrob Agents Chemother. 2009 Mar;53(3):1013-8. Epub 2008 Dec 29.
Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
Jin BS, Ryu JR, Ahn K, Yu YG.
AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1797-804.
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K, Shishido A, Root MJ.
J Biol Chem. 2009 Feb 6;284(6):3619-27. Epub 2008 Dec 10.
Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, Sakagami Y, Oishi S, Ohkubo T, Kobayashi Y, Otaka A, Fujii N, Matsuoka M.
Int J Biochem Cell Biol. 2009 Apr;41(4):891-9. Epub 2008 Sep 10.
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.
Biochemistry. 2007 Apr 10;46(14):4360-9. Epub 2007 Mar 20.
Membrane-perturbing domains of HIV type 1 glycoprotein 41.
Mobley PW, Pilpa R, Brown C, Waring AJ, Gordon LM.
AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):311-27.
Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.
Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, Hanson CV, Bomsel M, Mor TS.
Curr HIV Res. 2008 May;6(3):218-29.
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
J Mol Biol. 2004 Jun 25;340(1):9-14.
Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, Schleif WA, Miller MD, Geleziunas R, Pessi A.
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12903-8. Epub 2005 Aug 29.
Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB, Egelhofer M, von Laer D.
J Virol. 2006 Apr;80(7):3249-58.
C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ, Lambert DM, Tompkins WA.
J Virol. 2002 Sep;76(18):9079-86.
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM, Kim PS.
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.
Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
Miyauchi K, Kozlov MM, Melikyan GB.
PLoS Pathog. 2009 Sep;5(9):e1000585. Epub 2009 Sep 18.
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW.
J Virol. 2005 Apr;79(8):4991-9.
Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1.
Coutant J, Yu H, Clément MJ, Alfsen A, Toma F, Curmi PA, Bomsel M.
FASEB J. 2008 Dec;22(12):4338-51. Epub 2008 Sep 5.
Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
Steffen I, Pöhlmann S.
Curr Pharm Des. 2010;16(9):1143-58.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on